Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET
Aquestive Therapeutics (NASDAQ: AQST), a pharmaceutical company focused on innovative medicine delivery technologies, has scheduled its first quarter 2025 financial results announcement for May 12, 2025, after market close. The company will host a conference call for investors on May 13, 2025, at 8:00 a.m. ET to discuss the quarterly results and provide business updates.
Investors can participate by registering in advance to obtain call-in details. A live webcast will be available on Aquestive's Investors website section, with a 30-day archive available after the call.
Aquestive Therapeutics (NASDAQ: AQST), un'azienda farmaceutica specializzata in tecnologie innovative per la somministrazione di farmaci, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 12 maggio 2025, dopo la chiusura del mercato. La società terrà una conference call per gli investitori il 13 maggio 2025 alle 8:00 ET per discutere i risultati trimestrali e fornire aggiornamenti aziendali.
Gli investitori possono partecipare registrandosi in anticipo per ricevere i dettagli per la chiamata. Una diretta web sarà disponibile nella sezione Investitori del sito di Aquestive, con un archivio accessibile per 30 giorni dopo la chiamata.
Aquestive Therapeutics (NASDAQ: AQST), una compañía farmacéutica enfocada en tecnologías innovadoras para la administración de medicamentos, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 12 de mayo de 2025, después del cierre del mercado. La empresa realizará una llamada conferencia para inversores el 13 de mayo de 2025 a las 8:00 a.m. ET para discutir los resultados trimestrales y proporcionar actualizaciones comerciales.
Los inversores pueden participar registrándose con anticipación para obtener los detalles de la llamada. Habrá una transmisión en vivo disponible en la sección de Inversores del sitio web de Aquestive, con un archivo accesible por 30 días después de la llamada.
Aquestive Therapeutics (NASDAQ: AQST)는 혁신적인 의약품 전달 기술에 주력하는 제약회사로, 2025년 1분기 재무 결과 발표를 2025년 5월 12일 장 마감 후에 예정하고 있습니다. 회사는 2025년 5월 13일 오전 8시 ET에 투자자들을 위한 컨퍼런스 콜을 개최하여 분기 실적과 사업 업데이트를 논의할 예정입니다.
투자자들은 사전에 등록하여 전화 접속 정보를 받을 수 있습니다. 생중계 웹캐스트는 Aquestive 투자자 웹사이트 섹션에서 제공되며, 콜 종료 후 30일간 아카이브가 제공됩니다.
Aquestive Therapeutics (NASDAQ : AQST), une société pharmaceutique spécialisée dans les technologies innovantes de délivrance de médicaments, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le 12 mai 2025, après la clôture du marché. La société tiendra une conférence téléphonique pour les investisseurs le 13 mai 2025 à 8h00 ET afin de discuter des résultats trimestriels et de fournir des mises à jour commerciales.
Les investisseurs peuvent participer en s'inscrivant à l'avance pour obtenir les détails de connexion. Une webdiffusion en direct sera disponible dans la section Investisseurs du site d'Aquestive, avec un archivage accessible pendant 30 jours après l'appel.
Aquestive Therapeutics (NASDAQ: AQST), ein Pharmaunternehmen, das sich auf innovative Medikamentenabgabetechnologien spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 12. Mai 2025 nach Börsenschluss geplant. Das Unternehmen wird am 13. Mai 2025 um 8:00 Uhr ET eine Telefonkonferenz für Investoren abhalten, um die Quartalsergebnisse zu besprechen und geschäftliche Updates zu geben.
Investoren können teilnehmen, indem sie sich im Voraus registrieren, um die Einwahldaten zu erhalten. Ein Live-Webcast wird im Investor-Bereich der Aquestive-Website verfügbar sein, mit einem 30-tägigen Archiv nach der Telefonkonferenz.
- None.
- None.
WARREN, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the first quarter ended March 31, 2025 and provide an update on recent developments in its business after market close on Monday, May 12, 2025.
Management will host a conference call for investors at 8:00 a.m. ET on Tuesday, May 13, 2025. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.
A live webcast of the call will be available on the Investors section of Aquestive’s website at: First Quarter 2025 Earnings Call.
Following the call, a replay of the webcast will be available on the Investors section of the Company’s website at https://investors.aquestive.com/events-and-presentations. The webcast will be archived for 30 days.
About Aquestive Therapeutics
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has four commercialized products marketed by its licensees in the U.S. and around the world, and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an earlier stage epinephrine prodrug topical gel for various dermatology conditions including alopecia areata. For more information, visit Aquestive.com and follow us on LinkedIn.
Forward-Looking Statement
Certain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.
PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.
Investor Inquiries
Astr Partners
Brian Korb
Brian.korb@astrpartners.com
FAQ
When will Aquestive Therapeutics (AQST) report Q1 2025 earnings?
What time is Aquestive Therapeutics (AQST) Q1 2025 earnings call?
How can investors access AQST's Q1 2025 earnings call?
How long will AQST's Q1 2025 earnings call replay be available?
